Status:
ACTIVE_NOT_RECRUITING
Salt-Sensitivity and Immunity Cell Activation
Lead Sponsor:
Vanderbilt University Medical Center
Conditions:
High Blood Pressure
Salt; Excess
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
PHASE2
Brief Summary
Salt-sensitive hypertension affects nearly 50% of the hypertensive and 25% of the normotensive population, and strong evidence indicates that reducing salt intake decreases blood pressure and cardiova...
Detailed Description
The investigators will employ the Weinberger protocol in 20 patients as previously reported. They will advise participants to maintain their usual diet and salt consumption until the onset of the prot...
Eligibility Criteria
Inclusion
- We will perform a pilot analysis in 20 hypertensive subjects controlled for gender (50% men, 50% women), age (18-60 years),
- New or pre-existing diagnosis of essential hypertension defined as systolic blood pressure \>140 mmHg or \>90 mmHg diastolic or taking antihypertensive medications regardless of current blood pressure.
- BMI (18.5-24.9).
- Only subjects who give informed consent will be studied.
Exclusion
- Acute cardiovascular event(s) within the previous 6 months
- Claustrophobia precluding obtaining an MRI
- Inability to understand the nature, scope, and possible consequences of the study or to participate in/comply with the protocol.
- Current excessive alcohol or illicit drug use.
- Blood pressure below the inclusion criteria levels after discontinuation of therapy
- Presence of metal implants such as artificial joints.
- Concomitant diabetes mellitus, type I or II.
- Autoimmune disease.
- Recent vaccination
- Younger or older that inclusion criteria.
- Pregnancy.
Key Trial Info
Start Date :
September 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 15 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03753204
Start Date
September 1 2021
End Date
September 15 2026
Last Update
October 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232